Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates
- 24 March 2012
- journal article
- Published by Wiley in Parasite Immunology
- Vol. 34 (7) , 360-371
Abstract
Summary: Visceral leishmaniasis (VL) is a serious lethal parasitic disease caused by Leishmania donovani in Asia and by Leishmania infantum chagasi in southern Europe and South America. VL is endemic in 47 countries with an annual incidence estimated to be 500 000 cases. This high incidence is due in part to the lack of an efficacious vaccine. Here, we introduce an innovative approach to directly identify parasite vaccine candidate antigens that are abundantly produced in vivo in humans with VL. We combined RP‐HPLC and mass spectrometry and categorized three L. infantum chagasi proteins, presumably produced in spleen, liver and bone marrow lesions and excreted in the patients’ urine. Specifically, these proteins were the following: Li‐isd1 (XP_001467866.1), Li‐txn1 (XP_001466642.1) and Li‐ntf2 (XP_001463738.1). Initial vaccine validation studies were performed with the rLi‐ntf2 protein produced in Escherichia coli mixed with the adjuvant BpMPLA‐SE. This formulation stimulated potent Th1 response in BALB/c mice. Compared to control animals, mice immunized with Li‐ntf2+ BpMPLA‐SE had a marked parasite burden reduction in spleens at 40 days post‐challenge with virulent L. infantum chagasi. These results strongly support the proposed antigen discovery strategy of vaccine candidates to VL and opens novel possibilities for vaccine development to other serious infectious diseases.Keywords
This publication has 62 references indexed in Scilit:
- KSAC, the First Defined Polyprotein Vaccine Candidate for Visceral LeishmaniasisClinical and Vaccine Immunology, 2011
- Transplacental Transmission of Leishmania infantum as a Means for Continued Disease Incidence in North AmericaPLOS Neglected Tropical Diseases, 2011
- A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasisVaccine, 2011
- Optimized subunit vaccine protects against experimental leishmaniasisVaccine, 2009
- Spread of Vector-borne Diseases and Neglect of Leishmaniasis, EuropeEmerging Infectious Diseases, 2008
- Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial moleculesClinical and Experimental Immunology, 2008
- A Leishmania infantum cytosolic tryparedoxin activates B cells to secrete interleukin‐10 and specific immunoglobulinImmunology, 2008
- Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvantVaccine, 2007
- Evaluation of a latex agglutination test (KAtex) for detection of Leishmania antigen in urine of patients with HIV-Leishmania coinfection: value in diagnosis and post-treatment follow-upEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Induction of Th1 and Th2 CD4+ subsets during murine Leishmania major infectionResearch in Immunology, 1991